BDPT — BioAdaptives Income Statement
0.000.00%
- $0.65m
- $0.95m
- $0.03m
Annual income statement for BioAdaptives, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.01 | 0.016 | 0.02 | 0.017 | 0.029 |
Cost of Revenue | |||||
Gross Profit | 0.005 | 0.006 | 0.01 | 0.007 | 0.011 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.244 | 0.271 | 0.707 | 0.439 | 0.271 |
Operating Profit | -0.234 | -0.254 | -0.687 | -0.422 | -0.242 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.239 | -0.847 | -1.05 | -0.896 | -0.712 |
Net Income After Taxes | -0.239 | -0.847 | -1.05 | -0.896 | -0.712 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.239 | -0.847 | -1.05 | -0.896 | -0.712 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.239 | -0.847 | -1.05 | -0.896 | -0.712 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.013 | -0.042 | -0.03 | -0.008 | -0.001 |